Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsNancy Sullivan, Bimal Chakrabarti, Zhi-Yong Yang, Maria Grazia Pau, Jaap Goudsmit, Gary Nabel
Estimating the term…
The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.
A nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located at amino acid position 71 or 102 in Ebola Zaire of SEQ ID NO:
A nucleic acid molecule having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8, or insert thereof encoding modified or wild type filovirus GP.
Dependencies are inferred from the claim text.